Cabaletta Bio (NASDAQ:CABA) executives said newly released EULAR data support the company’s strategy to advance its lead cell therapy candidate, rese-cel, across multiple autoimmune diseases, including myositis, scleroderma and lupus. Speaking during a fireside chat, Chief Executive Officer Steven Nichtberger said Cabaletta has now treated more than 50 patients with rese-cel across “five or six […]